
Biosimilars
Latest News
Latest Videos

Shorts
More News

As concerns about GLP-1 costs grow, employers could be overlooking an even more pervasive condition driving healthcare spending.

From $37 billion to nearly $71 billion in a decade: a look at the forces driving biosimilars' next growth phase.

A new study from UCLA has found that insurers saw $3,820 lower monthly costs from the use of biosimilars. Cancer patients saved $39.50 in monthly out-of-pocket costs.

In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, discusses how biosimilars have improved access to biologics, but more work needs to be done for patients to see cost reductions.

As a wave of blockbuster biologics face loss of exclusivity, some hope that there may be a “second phase” of biosimilar adoption.

Cardinal Health 2026 Biosimilars Report shows biosimilars’ savings surge, but predictable reimbursement drives physician adoption amid FDA streamlining.

To gain approvals, biosimilar manufacturers could do faster, less expensive analytical studies of their products' composition.

The biosimilar market experienced 16 new approvals by early December 2025, marking significant expansion and introducing previously unavailable biosimilar drug classes to patients.

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

A budget model analysis finds that biosimilars for Prolia and Xgeva could provide cost savings for health plans.

The findings in a new study published in Health Affairs suggest that Semglee’s interchangeability status may have partially increased adoption by supporting improved formulary coverage.

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States under a restricted-distribution program because of the drug’s risk of progressive multifocal leukoencephalopathy.

The FDA has approved Poherdy as the first interchangeable biosimilar to Perjeta, expanding treatment options for adults with HER2-positive breast cancer across both early-stage and metastatic settings.

Increased adoption of biosimilars requires regulatory changes, educational efforts, and PBM reimbursement policies that enable fair competition, argues Dr. Benjamin Rome in a new paper.

Biosimilars enhance arthritis treatment access, with rising adoption among women and long-term patients, revealing key prescribing patterns in Turkey.


Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease marked by excessive blood vessel growth in adults.

A recent study finds that despite biosimilar use rising to 60% to 86% for three cancer drugs, predicted savings don’t match those that would be achieved from a site-neutral reimbursement strategy.

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing patient access and competition.







































